ClinicalTrials.gg
RecruitingNCT06383871Updated Jan 21, 2026

A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour

A Phase 1 interventional study of HRS-7058 capsule/ HRS-7058 tablet in Advanced Malignant Tumour, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
233
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-7058.

02

Conditions studied

  • Advanced Malignant Tumour
03

In context

Lead sponsor

Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects gave to the study before participating in, and voluntarily signed informed consent;
  2. 18 to 75 years old (including both ends), gender is not limited;
  3. Subjects with locally advanced or solid tumour confirmed by histopathology;
  4. Having at least one evaluable or according to the solid tumour response Evaluation Criteria ( 1.1);
  5. Performance Status of 0 or 1;
  6. The expected survival time is more than 3 months;
  7. Be able to ingest drugs and be able to comply with trial and follow-up procedures;
  8. Adequate bone marrow and organ function;
  9. Fertile women must agree to abstain from sex (abstaining from heterosexual intercourse) or use a highly effective method of for at least one week from the time they sign an informed consent form until the last dose of the study drug. The blood HCG test must be negative within 7 days before the start of the study treatment, and must be non-lactating;
  10. For male patients whose partner is a woman of reproductive age, they must agree to abstain from sex for at least one week from signing the informed consent until the last dose of the study drug, or to use a highly effective method of contraception.

Exclusion criteria

Exclusion Criteria:

  1. Accompanied by untreated or active central nervous system (CNS) tumour ;
  2. Had other within five years prior to first use of the drug;
  3. With severe cardiovascular and cerebrovascular disease;
  4. nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications;
  5. The presence of uncontrolled pleural, abdominal or pericardial effusion;
  6. Severe infection within 4 weeks prior to initiation of study treatment;
  7. History of immune deficiency;
  8. The adverse reactions of previous anti-tumour therapy have not recovered to ≤ grade 1;
  9. Antitumor therapy such as chemotherapy, biotherapy, targeted therapy, immunotherapy, or other unmarketed investigational drug therapy within 4 weeks prior to initial use of the investigational drug;
  10. Had undergone major organ surgery within 4 weeks prior to the first use of the study drug;
  11. Women who are pregnant, breastfeeding, or who plan to become pregnant within one week of their last use of the study drug during the study period;
  12. Known allergies and to the investigational drug or any of its components;
  13. In the investigator's judgment, the subjects had other factors that could have affected the study results or led to the forced termination of the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
233 participants (estimated)

Study arms

  • Experimental
    HRS-7058

    Drug: HRS-7058 capsule/ HRS-7058 tablet

Interventions

  • DrugHRS-7058 capsule/ HRS-7058 tablet

    HRS-7058 capsule/ HRS-7058 tablet

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months

  2. maximum tolerated dose (MTD)

    Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months

  3. Phase II recommended dose (RP2D)

    Time frame: From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months

  4. Safety endpoints: adverse events (AE)

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 21 months]

Secondary outcomes

  1. Efficacy endpoints: Objective response rate (ORR) assessed based on RECIST v1.1 criterion

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 21 months

  2. Efficacy endpoints: duration of response (DoR) assessed based on RECIST v1.1 criterion

    Time frame: From the beginning of first patient in (FPI) to the end of study up to approximately 21 months

  3. Efficacy endpoints: disease control rate (DCR) assessed based on RECIST v1.1 criterion

    Time frame: From the beginn ing of first patient in (FPI) to the end of study up to approximately 21 months

  4. Efficacy endpoints: progression-free survival (PFS) assessed based on RECIST v1.1 criterion

    Time frame: From the beginn ing of first patient in (FPI) to the end of study up to approximately 21 months

  5. Efficacy endpoints: overall survival (OS)

    Time frame: From the beginn ing of first patient in (FPI) to the end of study up to approximately 21 months

07

Study locations

1 of 1 sites recruiting
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
    Recruiting
    • Dingzhi Huang · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2024
First posted
Apr 25, 2024
StartActual
Jun 6, 2024
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06383871
Responsible party
Sponsor
First posted
Apr 25, 2024
Start date
Jun 6, 2024
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jan 21, 2026

Study contacts

Yifan Zhang
Contact
yifan.zhang.yz597@hengrui.com
+0518-81220121
Keke Yan
Contact
keke.yan@hengrui.com
+0518-81220121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion